Simple Summary Reduced response to glucocorticoids (GCs, such as dexamethasone,
Dex), first-line drugs employed during therapy induction, is considered a poor prognosis …

Glucocorticoid (GC) resistance remains a major obstacle to successful treatment of lymphoid
malignancies. Till now, the precise mechanism of GC resistance remains unclear. In the …

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Treatments
include glucocorticoids (GCs) such as dexamethasone (Dex) and prednisolone, which may …

Glucocorticoids (GCs) are a central component of multi-drug treatment protocols against T
and B acute lymphoblastic leukemia (ALL), which are used intensively during the remission …

Glucocorticoid (GC) resistance in children with acute lymphoblastic leukemia (ALL) usually
resulted in the failure of treatment. Exploring new agents to overcome GC resistance is …

Glucocorticoids (GCs) are among the most important drugs for acute lymphoblastic
leukaemia (ALL), yet despite their clinical importance, the exact mechanisms involved in GC …

Approximately 20% of pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients are
currently incurable due to primary or secondary resistance to glucocorticoid-based …

Acute lymphoblastic leukaemia (ALL) is the most frequent childhood cancer and, although it
is highly treatable, resistance to therapy, toxicity and side effects remain challenging. The …

Glucocorticoids (GCs) are metabolic hormones with immunosuppressive effects that have
proven effective drugs against childhood acute lymphoblastic leukemia (ALL). Yet, the role …

Drug‐resistant forms of acute lymphoblastic leukaemia (ALL) are a leading cause of death
from disease in children. Up to 25% of patients with T‐cell ALL (T‐ALL) develop resistance …